Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain

Molecular Pain

Volumn 10, Issue 1, 2014, Pages

  Rojewska, Ewelina ^a   Korostynski, Michal ^a   Przewlocki, Ryszard ^a   Przewlocka, Barbara ^a   Mika, Joanna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Microarray DNA; Minocycline; Neuropathic pain; Pain related genes

Indexed keywords

CD40 ANTIGEN; DECTIN 1; MESSENGER RNA; MINOCYCLINE; AMINO ACID TRANSPORTER; ANALGESIC AGENT; CYTIDINE DEAMINASE; LECTIN; MEMBRANE PROTEIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOBEC3B GENE; ARTICLE; CD40 GENE; CONTROLLED STUDY; DECTIN 1 GENE; DNA MICROARRAY; DRUG EFFICACY; DRUG MECHANISM; FAM22F GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GIMAP5 GENE; HYPERALGESIA; MALE; NEUROPATHIC PAIN; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RAT; RWDD3 GENE; SLC7A7 GENE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEMISPHERIC DOMINANCE; METABOLISM; PAIN MEASUREMENT; PAIN THRESHOLD; PATHOLOGY; SCIATICA; SPINAL CORD; WISTAR RAT;

AMINO ACID TRANSPORT SYSTEM Y+; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTIGENS, CD40; CYTIDINE DEAMINASE; DISEASE MODELS, ANIMAL; FUNCTIONAL LATERALITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LECTINS, C-TYPE; MALE; MEMBRANE GLYCOPROTEINS; MINOCYCLINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, WISTAR; SCIATICA; SPINAL CORD;

EID: 84905968215     PISSN: 17448069     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-10-47     Document Type: Article

References (85)

1. Austin PJ, Moalem-Taylor G. The neuroimmune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 2010, 229:26-50.
2. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001, 90:1-6.
3. Lee ML, Sciorra LJ. Partial monosomy of the long arm of chromosome 11 in a severely affected child. Ann Genet 1981, 24:51-53.
4. Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol 2013, 716:106-119.
5. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
6. Lundblad R, Ekstrom P, Giercksky KE. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995, 3:210-215.
7. Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007, 560:142-149.
8. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Gru¨nwald C, Knobler R, Schwarz A, Luger TA, Schwarz T. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994, 83:262-267.
9. Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 2003, 104:655-664.
10. Sweitzer SM, Schubert P, DeLeo JA. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 2001, 297:1210-1217.
11. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001, 103:529-539.
12. Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, Chen PX, Feng JQ. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 2008, 22:114-123.
13. Hains BC, Waxman SG. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci 2006, 26:4308-4317.
14. Mika J, Osikowicz M, Rojewska E, Korostynski M, Wawrzczak-Bargiela A, Przewlocki R, Przewlocka B. Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol 2009, 623:65-72.
15. Mika J, Rojewska E, Makuch W, Przewlocka B. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience 2010, 165:1420-1428.
16. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996, 93:14014-14029.
17. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 1980, 176:1061-1068.
18. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 791:337-343.
19. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001, 21:2580-2588.
20. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001, 166:7527-7533.
21. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
22. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004, 3:744-751.
23. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004, 17:359-366.
24. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004, 24:2182-2190.
25. Yrjanheikki J, Keina¨nen R, Pellikka M, Ho¨kfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998, 95:15769-15774.
26. Yrjanheikki J, Tikka T, Keina¨nen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 1999, 96:13496-13500.
27. Ledeboer A, Gamanos M, Lai W, Martin D, Maier SF, Watkins LR, Quan N. Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur J Neurosci 2005, 22:1977-1986.
28. Mishra MK, Dutta K, Saheb SK, Basu A. Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochem Int 2009, 55:717-723.
29. Speth C, Dierich MP, Gasque P. Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 2002, 38:669-679.
30. Rodriguez Parkitna J, Korostynski M, Kaminska-Chowaniec D, Obara I, Mika J, Przewlocka B, Przewlocki R. Comparison of gene expression profiles in neuropathic and inflammatory pain. J Physiol Pharmacol 2006, 57:401-414.
31. Vega-Avelaira D, Ge´ranton SM, Fitzgerald M. Differential regulation of immune responses and macrophage/neuron interactions in the dorsal root ganglion in youngand adult rats following nerve injury. Mol Pain 2009, 5:70.
32. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008, 70:1630-1635.
33. Beniczky S, Tajti J, Ti´mea Varga E, Ve´csei L. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm 2005, 112:735-749.
34. Backonja MM, Miletic G, Miletic V. The effect of continuous morphine analgesia on chronic thermal hyperalgesia due to sciatic constriction injury in rats. Neurosci Lett 1995, 196:61-64.
35. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, Fontana DJ. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997, 324:153-160.
36. Makuch W, Mika J, Rojewska E, Zychowska M, Przewlocka B. Effects of selective and non-selective inhibitors of nitric oxide synthase on morphine- and endomorphin-1-induced analgesia in acute and neuropathic pain in rats. Neuropharmacology 2013, 75:445-457.
37. Mika J, Rojewska E, Makuch W, Korostynski M, Luvisetto S, Marinelli S, Pavone F, Przewlocka B. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 2011, 175:358-366.
38. Obara I, Parkitna JR, Korostynski M, Makuch W, Kaminska D, Przewlocka B, Przewlocki R. Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain 2009, 141:283-291.
39. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain 2001, 93:201-205.
40. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
41. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6:521-532.
42. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43.
43. Garlichs CD, Kozina S, Fateh-Moghadam S, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeier A, Yilmaz A, Ludwig J, Neundorfer B, Daniel WG. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418.
44. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Microglial activation resulting from CD40-CD40L interaction after b-amyloid stimulation. Science 1999, 286:2352-2355.
45. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJA, Claassen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1996, 93:2499-2504.
46. Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med 2001, 193:967-974.
47. Grewal I, Foellmer H, Grewal K, Xu J, Hardardottir F, Baron J, Janeway C, Flavell R. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996, 273:1864-1867.
48. Nguyen V, Walker WS, Benveniste EN. Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-b. Eur J Immunol 1998, 28:2537-2548.
49. Nguyen VT, Benveniste EN. Critical role of TNF-a and NFkB in IFN-c-induced CD40 expression in microglia/macrophages. J Biol Chem 2002, 277:13796-13803.
50. Cao L, Beaulac H, Eurich A. Differential lumbar spinal cord responses among wild type, CD4 knockout, and CD40 knockout mice in spinal nerve L5 transection-induced neuropathic pain. Mol Pain 2012, 8:88.
51. Brown G. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006, 6:33-43.
52. Salazar-Aldrete C, Gala´n-Di´ez M, Ferna´ndez-Ruiz E, Niño-Moreno P, Estrada-Capetillo L, Abud-Mendoza C, Layseca-Espinosa E, Baranda L, Gonza´lez-Amaro R. Expression and function of dectin-1 is defective in monocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 2013, 33:368-377.
53. Viriyakosol S, Jimenez Mdel P, Gurney MA, Ashbaugh ME, Fierer J. Dectin-1 is required for resistance to coccidioidomycosis in mice. MBio 2013, 4:e00597-e00612.
54. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, 494:366-370.
55. Lada AG, Dhar A, Boissy RJ, Hirano M, Rubel AA, Rogozin IB, Pavlov YI. AID/APOBEC cytosine deaminase induces genome-wide kataegis. Biol Direct 2012, 18:7-47.
56. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013, 45:970-976.
57. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2013, 16:e00534.
58. Kuong KJ, Loeb LA. APOBEC3B mutagenesis in cancer. Nat Genet 2013, 45:964-965.
59. He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 2009, 3:195-206.
60. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S, Neri A. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res 2011, 17:7402-7412.
61. Fan S, Zhao Y, Li X, Du Y, Wang J, Song X, Zhou F, Chen H, Chen G, Zhao Y, Mao Y, Lan Q. Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population. Exp Biol Med 2013, 238:1075-1081.
62. Xie L, Song X, Yu J, Guo W, Wei L, Liu Y, Wang X. Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer. J Cancer Res Clin Oncol 2011, 137:1739-1747.
63. Borsani G, Bassi MT, Sperandeo MP, De Grandi A, Buoninconti A, Riboni M, Manzoni M, Incerti B, Pepe A, Andria G, Ballabio A, Sebastio G. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet 1999, 21:297-301.
64. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Gatti R, Dionisi-Vici C, Martinelli D, Goffredo BM, Font-Llitjo´s M, Mariani F, Luisetti M, Dall'Asta V. Impaired phagocytosis in macrophages from patients affected by lysinuric protein intolerance. Mol Genet Metab 2012, 105:585-589.
65. Bonaldo MF, Lennon G, Soares MB. Normalization and subtraction: two approaches to facilitate gene discovery. Genome Res 1996, 6:791-806.
66. Huang CC, Tu SH, Lien HH, Jeng JY, Huang CS, Huang CJ, Lai LC, Chuang EY. Concurrent gene signatures for han chinese breast cancers. PLoS One 2013, 8:e76421.
67. Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, Kim DS, Park JS, Cho HJ. Spinal NF-kappaB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci 2004, 19:3375-3381.
68. Bergmann TK, Vach W, Feddersen S, Eckhoff L, Gre´en H, Herrstedt J, Brosen K. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 2013, 52:871-874.
69. Schneider B, Li K, Miller K, Flockhart DA, Radovich M, Han Cock BA. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103 [abstracts 1000]. ASCO Meeting 2011, http://meetinglibrary.asco.org/content/78499-102.
70. Carter C, Dion C, Schnell S, Coadwell WJ, Graham M, Hepburn L, Morgan G, Hutchings A, Pascall JC, Jacobs H, Miller JR, Butcher GW. A natural hypomorphic variant of the apoptosis regulator Gimap4/IAN1. J Immunol 2007, 179:1784-1795.
71. Dalberg U, Markholst H, Hornum L. Both Gimap5 and the diabetogenic BBDP allele of Gimap5 induce apoptosis in T cells. Int Immunol 2007, 19:447-453.
72. Nitta T, Nasreen M, Seike T, Goji A, Ohigashi I, Miyazaki T, Ohta T, Kanno M, Takahama Y. IAN family critically regulates survival and development of T lymphocytes. PLoS Biol 2006, 4:e103.
73. Nitta T, Takahama Y. The lymphocyte guard-IANs: regulation of lymphocyte survival by IAN/GIMAP family proteins. Trends Immunol 2007, 28:58-65.
74. Filen JJ, File´n S, Moulder R, Tuomela S, Ahlfors H, West A, Kouvonen P, Kantola S, Bjo¨rkman M, Katajamaa M, Rasool O, Nyman TA, Lahesmaa R. Quantitative proteomics reveals GIMAP family proteins 1 and 4 to be differentially regulated during human T helper cell differentiation. Mol Cell Proteomics 2009, 8:32-44.
75. Pandarpurkar M, Wilson-Fritch L, Corvera S, Markholst H, Hornum L, Greiner DL, Mordes JP, Rossini AA, Bortell R. Ian4 is required for mitochondrial integrity and T cell survival. Proc Natl Acad Sci U S A 2003, 100:10382-10387.
76. Aksoylar HI, Lampe K, Barnes MJ, Plas DR, Hoebe K. Loss of immunological tolerance in Gimap5-deficient mice is associated with loss of Foxo in CD4+ T cells. J Immunol 2012, 188:146-154.
77. Chen XL, Serrano D, Mayhue M, Wieden HJ, Stankova J, Boulay G, Ilangumaran S, Ramanathan S. GTPase of the immune-associated nucleotide-binding protein 5 (GIMAP5) regulates calcium influx in T-lymphocytes by promoting mitochondrial calcium accumulation. Biochem J 2013, 449:353-364.
78. Moralejo DH, Fuller JM, Rutledge EA, Van Yserloo B, Ettinger RA, Jensen R, Osborne W, Kwitek A, Lernmark A. BB rat Gimap gene expression in sorted lymphoid T and B cells. Life Sci 2011, 89:748-754.
79. Chen Y, Yu M, Dai X, Zogg M, Wen R, Weiler H, Wang D. Critical role for Gimap5 in the survival of mouse hematopoietic stem and progenitor cells. J Exp Med 2011, 208:923-935.
80. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
81. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
82. Sorkin L, Svensson CI, Jones-Cordero TL, Hefferan MP, Campana WM. Spinal p38 mitogen-activated protein kinase mediates allodynia induced by first-degree burn in the rat. J Neurosci Res 2009, 87:948-955.
83. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
84. Korostynski M, Piechota M, Dzbek J, Mlynarski W, Szklarczyk K, Ziolkowska B, Przewlocki R. Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. BMC Genomics 2013, 14:606.
85. Piechota M, Korostynski M, Solecki W, Gieryk A, Slezak M, Bilecki W, Ziolkowska B, Kostrzewa E, Cymerman I, Swiech L, Jaworski J, Przewlocki R. The dissection of transcriptional modules regulated by various drugs of abuse in the mouse striatum. Genome Biol 2010, 11:R48.